Charcot-Marie-Tooth disease (CMT) is a hereditary sensory-motor neuropathy affecting between 30,000 and 50,000 people in France (or 1 in every 2,500 people affected). More than 80 genes involved in the onset and transmission of this disease have been identified, and each gene corresponds to a distinct form of the disease.
- NMD670: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
Acronym |
NMD670 |
| Pathology | CMT1A |
| Intervention | NMD670 |
| Principal investigator | Marion Masingue |
| Sponsor | NMD PHARMA |
| Study status | Active |
| Recruitment status | Ongoing |
| Population | Adult |
| Â | + infos sur clinicaltrials.gov |
Contact : essais-adultes@institut-myologie.org
